 |
5-amino-1-(2-methyl-1H-benzo[d]imidazol-5-yl)-1H-pyrazol-4-yl 1H-indol-2-yl ketone mono[(S)-2-hydroxysuccinate] |
|---|---|
| Trade Name | |
| Orphan Indication | Biliary tract cancer |
| EU Market Approval | EU |
| EU Designation Date | 2017-10-16 00:00:00 |
| Sponsor | Voisin Consulting S.A.R.L. |
